 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Celgene Corporation (CELG) discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe.
Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum.
The companys commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia.
The companys pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor.
Shares have formed a bullish "cup & handle" and higher share prices are expected for this stock.
52-Week Trading Range: $77.22 - $173.80
Entry Point: $169.00
Stop Loss: $160.55
Target Price: $185.90
CELG fell below our stop loss after it was downgraded this morniing. We do still believe in the company and its product line.
